Results 51 to 60 of about 27,791 (179)

Safety pharmacology of acute mescaline administration in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber, Mélusine Humbert‐Droz, Laura Ley, Yasmin Schmid, Matthias E. Liechti   +4 more
wiley   +1 more source

Effects of Constant Flickering Light on Refractive Status, 5-HT and 5-HT2A Receptor in Guinea Pigs. [PDF]

PLoS ONE, 2016
To investigate the effects of constant flickering light on refractive development, the role of serotonin (i.e.5-hydroxytryptamine, 5-HT)and 5-HT2A receptor in myopia induced by flickering light in guinea pigs.Forty-five guinea pigs were randomly divided ...
Bing Li, Xiumei Luo, Tao Li, Changyue Zheng, Shunmei Ji, Yuanyuan Ma, Shuangshuang Zhang, Xiaodong Zhou   +7 more
doaj   +1 more source

Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study. [PDF]

, 2017
ObjectiveParkinson's disease psychosis (PDP) is a frequent complication of idiopathic Parkinson's disease (iPD) with significant impact on quality of life and association with poorer outcomes.
Bizzarri, Cummings, Fernandez, Fernandez, Fénelon, Gama, Goldman, Hack, Hubbard, Kiferle, Lertxundi, McFarland, Meltzer, Meral, Mesquita, Mocci, Munhoz, Noel, Pagonabarraga, Prohorov, Rabey, Reichmann, Rolland, Seppi, Shotbolt, Starkstein, Thomas, Vanover, Weintraub, Zhu   +29 more
core   +2 more sources

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Liraglutide, a GLP-1 Receptor Agonist, Which Decreases Hypothalamic 5-HT2A Receptor Expression, Reduces Appetite and Body Weight Independently of Serotonin Synthesis in Mice

Journal of Diabetes Research, 2018
A recent report suggested that brain-derived serotonin (5-HT) is critical for maintaining weight loss induced by glucagon-like peptide-1 (GLP-1) receptor activation in rats and that 5-HT2A receptors mediate the feeding suppression and weight loss induced
Katsunori Nonogaki, Takao Kaji
doaj   +1 more source

The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function. [PDF]

PLoS ONE, 2014
There is considerable interest in defining new agents or targets for antithrombotic purposes. The 5-HT2A receptor is a G-protein coupled receptor (GPCR) expressed on many cell types, and a known therapeutic target for many disease states.
Olivia A Lin, Zubair A Karim, Hari Priya Vemana, Enma V P Espinosa, Fadi T Khasawneh   +4 more
doaj   +1 more source

Nefazodone in psychotic unipolar and bipolar depression: A retrospective chart analysis and open prospective study on its efficacy and safety versus combined treatment with amitriptyline and haloperidol [PDF]

, 2002
Although atypical antipsychotics are on the rise, traditional treatment of psychotic (or delusional) depression mostly includes the addition of classical antipsychotics to antidepressants. As there are only few data supporting this approach compared with
Born, Christoph, Grunze, Heinz, Marcuse, Alain, Schaerer, Lars O., Walden, Jörg   +4 more
core   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Genotype-Dependent Difference in 5-HT2C Receptor-Induced Hypolocomotion: Comparison with 5-HT2A Receptor Functional Activity

Neural Plasticity, 2015
In the present study behavioral effects of the 5-HT2C serotonin receptor were investigated in different mouse strains. The 5-HT2C receptor agonist MK-212 applied intraperitoneally induced significant dose-dependent reduction of distance traveled in the ...
Darya V. Bazovkina, Elena M. Kondaurova, Vladimir S. Naumenko, Evgeni Ponimaskin   +3 more
doaj   +1 more source

The effect of 5-HT2a/2c receptor agonist microinjected into central amygdaloid nucleus and median preoptic area on maternal aggressive behavior in rats Efeito sobre o comportamento materno agressivo de ratos da microinjeção do agonista seletivo de receptores 5-HT2a/2c no núcleo central da amígdala e na área pré-óptica medial

Brazilian Journal of Psychiatry, 2006
OBJECTIVE: Much evidence supports the hypothesis that 5-hydroxytryptamine (5-HT) activation is related to the inhibition of aggression. We examined potentially pro- and anti-aggressive effects of the 5-HT2A/2C receptor agonist on specific brain sites ...
Rosa Maria Martins de Almeida, Marcia Giovenardi, Simone Perroni da Silva, Verônica Paz de Oliveira, Dirson João Stein   +4 more
doaj   +1 more source